NasdaqGS:RPRXPharmaceuticals
How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma
In August 2026, Royalty Pharma plc agreed to provide US$100 million in funding to Zealand Pharma A/S in return for Zealand’s economic interests in rusfertide (PTG-300), including a 1% royalty on potential future global net sales and associated milestone payments, with payments split between closing and the first anniversary.
This deal gives Royalty Pharma exposure to a potential first-in-class therapy for polycythemia vera while leaving Zealand Pharma with a smaller upside royalty on very...